Paul Tudor Jones's GMED Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 8,432 shares of Globus Medical, Inc. (GMED) worth $736,198, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 44 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in GMED, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2024, adding 85,448 shares. Largest reduction occurred in Q4 2025, reducing 91,568 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Globus Medical (GMED) Holding Value Over Time
Track share changes against reported price movement
Quarterly Globus Medical (GMED) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -91,568 | Reduce 91.57% | 8,432 | $87.31 |
| Q2 2025 | +10,000 | Add 11.11% | 100,000 | $59.02 |
| Q1 2025 | -16,020 | Reduce 15.11% | 90,000 | $73.20 |
| Q4 2024 | -59,661 | Reduce 36.01% | 106,020 | $82.71 |
| Q3 2024 | +85,448 | Add 106.50% | 165,681 | $71.54 |
| Q2 2024 | +74,913 | Add 1408.14% | 80,233 | $68.49 |
| Q1 2024 | +5,320 | New Buy | 5,320 | $53.64 |
| Q4 2023 | -9,409 | Sold Out | 0 | $0.00 |
| Q3 2023 | -78,055 | Reduce 89.24% | 9,409 | $49.65 |
| Q2 2023 | +75,613 | Add 638.03% | 87,464 | $59.54 |
| Q1 2023 | -7,656 | Reduce 39.25% | 11,851 | $0.06 |
| Q4 2022 | +19,507 | New Buy | 19,507 | $0.07 |
| Q2 2022 | -35,969 | Sold Out | 0 | $0.00 |
| Q1 2022 | +35,969 | New Buy | 35,969 | $73.79 |
| Q4 2021 | -19,679 | Sold Out | 0 | $0.00 |
| Q3 2021 | +19,679 | New Buy | 19,679 | $76.63 |
| Q1 2021 | -4,253 | Sold Out | 0 | $0.00 |
| Q4 2020 | -4,161 | Reduce 49.45% | 4,253 | $65.13 |
| Q3 2020 | -20,291 | Reduce 70.69% | 8,414 | $49.56 |
| Q2 2020 | +14,873 | Add 107.53% | 28,705 | $47.73 |
| Q1 2020 | +13,832 | New Buy | 13,832 | $42.51 |
| Q2 2019 | -13,059 | Sold Out | 0 | $0.00 |
| Q1 2019 | -16,868 | Reduce 56.36% | 13,059 | $49.39 |
| Q4 2018 | +29,927 | New Buy | 29,927 | $43.27 |
| Q4 2017 | -7,736 | Sold Out | 0 | $0.00 |
| Q3 2017 | -9,915 | Reduce 56.17% | 7,736 | $29.73 |
| Q2 2017 | +8,751 | Add 98.33% | 17,651 | $33.14 |
| Q1 2017 | -2,300 | Reduce 20.54% | 8,900 | $29.66 |
| Q4 2016 | -72,893 | Reduce 86.68% | 11,200 | $24.82 |
| Q3 2016 | -33,404 | Reduce 28.43% | 84,093 | $22.57 |
| Q2 2016 | +17,214 | Add 17.17% | 117,497 | $23.83 |
| Q1 2016 | +70,515 | Add 236.88% | 100,283 | $23.75 |
| Q4 2015 | -25,227 | Reduce 45.87% | 29,768 | $27.82 |
| Q3 2015 | +37,230 | Add 209.57% | 54,995 | $20.66 |
| Q2 2015 | -1,267 | Reduce 6.66% | 17,765 | $25.67 |
| Q1 2015 | -25,958 | Reduce 57.70% | 19,032 | $25.22 |
| Q4 2014 | -7,505 | Reduce 14.30% | 44,990 | $23.76 |
| Q3 2014 | +24,273 | Add 86.01% | 52,495 | $19.68 |
| Q2 2014 | +28,222 | New Buy | 28,222 | $23.92 |
| Q1 2014 | -24,700 | Sold Out | 0 | $0.00 |
| Q4 2013 | +11,400 | Add 85.71% | 24,700 | $20.16 |
| Q3 2013 | +1,600 | Add 13.68% | 13,300 | $17.44 |
| Q2 2013 | +11,700 | Add 0.00% | 11,700 | $16.84 |
Paul Tudor Jones's Globus Medical Investment FAQs
Paul Tudor Jones first purchased Globus Medical, Inc. (GMED) in Q2 2013, acquiring 11,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Globus Medical, Inc. (GMED) for 44 quarters since Q2 2013.
Paul Tudor Jones's largest addition to Globus Medical, Inc. (GMED) was in Q3 2024, adding 165,681 shares worth $11.85 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 8,432 shares of Globus Medical, Inc. (GMED), valued at approximately $736,198.
As of the Q4 2025 filing, Globus Medical, Inc. (GMED) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Globus Medical, Inc. (GMED) was 165,681 shares, as reported at the end of Q3 2024.